PDCD1 and neoplasm: Treatment with immune checkpoint inhibitors, targeting cytotoxic T lymphocyte–associated protein 4 (CTLA4), programmed cell death protein-1 (PD-1) or its ligand (PD-L1) has provided substantial benefits to some patients with different tumor entities.